Dendreon reported second-quarter results ..... than our expectations, with solid Provenge sales. However, the ongoing lack ..... moat, negative trend ratings. Dendreon reported $82.2 million in Provenge sales for the quarter, a solid
Dendreon reported first-quarter results ..... expectations, with continued sluggish Provenge sales and lack of clarity on plans ..... moat, negative trend ratings. Dendreon reported $68.8 million in Provenge sales for the quarter, a slight
Dendreon reported fourth-quarter results ..... expectations. The stabilization of Provenge revenue and the announcement of the ..... estimate and our no-moat rating. Dendreon reported $74.8 million in Provenge sales for the quarter, up 10
(Reuters) - Biotechnology company Dendreon Corp said it would start selling its prostate cancer vaccine Provenge in Europe, sending its shares up nearly 15 percent in premarket trading.
Dendreon on Monday announced preliminary Provenge revenue for the fourth quarter ..... increasing competition in Provenge 's prechemotherapy indication ..... the current trajectory of Provenge 's sales, we think Dendreon will need to tap the equity
Dendreon reported second ..... its sole product, Provenge , due to ongoing ..... able to increase Provenge sales over last year ..... Additionally, Dendreon disclosed that CFO Greg ..... a decrease in our Provenge sales expectations
Dendreon DNDN announced that it received ..... Agency for the approval of Provenge , the firm's immunotherapy ..... this year, and we expect Dendreon to announce its commercialization ..... European launch this year. If Provenge does succeed in gaining
Dendreon DNDN reported dismal first ..... sales of its sole product Provenge plummet amid new competition ..... space. Though we believe Dendreon 's first quarter will be ..... these results as a clue to Provenge 's ultimate role within
(Reuters) - Sanford C. Bernstein upgraded Dendreon Corp to "outperform" from "market-perform" and said the drugmaker could be one of the best performers in 2013, sending its shares up 15 percent...
(Reuters) - Dendreon Corp on Friday said restructuring-related costs widened its quarterly loss but not as much as Wall Street had expected, and its shares jumped 20 percent.